Abstracts Archive - Page 1094 of 2425 - ACR Meeting Abstracts

Abstract Number: 1341 • 2018 ACR/ARHP Annual Meeting
Autoantibodies to Mi-2 Alpha and Mi-2 Beta in Patients with Myositis
Michaelin Richards¹, Ignacio Garcia-De La Torre², Yelitza Gonzalez-Bello³, Monica Vazquez-Del Mercado⁴, Lilia Andrade-Ortega⁵, Gabriel Medrano-Rameriz⁶, Jose Eduardo Navarro-Zarza⁷, Marco Maradiaga⁸, Esthela Loyo⁹, Armando Rojo-Mejía¹⁰, Graciela N Gómez¹¹, Andrea Seaman¹, Marvin J. Fritzler¹², Martial Koenig¹³ and Michael Mahler¹, ¹Research and Development, Inova Diagnostics, San Diego, CA, ²Immunology & Rheumatology, Centro de Est. de Invest. Bas. y Clin., S.C., Guadalajara, JAL, Mexico, ³Immunology and Rheumatology, Hospital General de Occidente, Secretaria de Salud Jalisco, Guadalajara, Jalisco, Mexico, ⁴Centro Universitario de Ciencias de la Salud, Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, Universidad de Guadalajara, Guadalajara, Mexico, ⁵Rheumatology Department, CMN 20 de Noviembre ISSSTE,, CDMX, Mexico, ⁶Hospital General de México, "Dr. Eduardo Liceaga, Mexico City, Mexico, ⁷Hospital General “Dr. Raymundo Abarca Alarcón”, Chilpancingo, Mexico, ⁸Centro de Investigación de Tratamientos Innovadores de Sinaloa, Culiacán, Mexico, ⁹Departamento de Reumatologia, Hospital Regional Universitario José Ma Cabral Baez, Santiago, Dominican Republic, ¹⁰Clínica San Pablo, Lima, Peru, ¹¹Diaz Colodrero 2537 8° A, Instituto de Investigaciones Medicas Alfredo Lanari, Capital Federal, Argentina, ¹²Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ¹³Internal Medicine, Hôpital Notre-Dame du CHUM, Montréal, QC, Canada
Background/Purpose: Myositis specific antibodies (MSA) represent not only important diagnostic tools, but also help stratify myositis patients with particular clinical features, treatment responses and disease…
Abstract Number: 1342 • 2018 ACR/ARHP Annual Meeting
Myositis Specific Antibodies Measured Using a Novel Particle Based Multi-Analyte Assay Resemble Myositis Subsets By Principle Component Analysis
Michaelin Richards¹, Ignacio Garcia de la Torre², Yelitza Gonzalez-Bello³, Monica Vazquez-Del Mercado⁴, Lilia Andrade-Ortega⁵, Gabriel Medrano-Rameriz⁶, Jose Eduardo Navarro-Zarza⁷, Marco Maradiaga⁸, Esthela Loyo⁹, Armando Rojo-Mejía¹⁰, Graciela N Gómez¹¹, Andrea Seaman¹, Marvin J. Fritzler¹² and Michael Mahler^1,13, ¹Research and Development, Inova Diagnostics, San Diego, CA, ²Hospital General de Occidente, Guadalajara, Mexico, ³Immunology and Rheumatology, Hospital General de Occidente, Secretaria de Salud Jalisco, Guadalajara, Jalisco, Mexico, ⁴Centro Universitario de Ciencias de la Salud, Instituto de Investigación en Reumatología y del Sistema Músculo Esquelético, Universidad de Guadalajara, Guadalajara, Mexico, ⁵Rheumatology Department, CMN 20 de Noviembre ISSSTE,, CDMX, Mexico, ⁶Hospital General de México, "Dr. Eduardo Liceaga, Mexico City, Mexico, ⁷Hospital General “Dr. Raymundo Abarca Alarcón”, Chilpancingo, Mexico, ⁸Centro de Investigación de Tratamientos Innovadores de Sinaloa, Culiacán, Mexico, ⁹Departamento de Reumatologia, Hospital Regional Universitario José Ma Cabral Baez, Santiago, Dominican Republic, ¹⁰Clínica San Pablo, Lima, Peru, ¹¹Diaz Colodrero 2537 8° A, Instituto de Investigaciones Medicas Alfredo Lanari, Capital Federal, Argentina, ¹²Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ¹³9900 Old Grove road, INOVA Diagnostics, San Diego, CA
Background/Purpose: Myositis specific antibodies (MSA) represent important diagnostic tools and also help stratify idiopathic inflammatory myositis (IIM) patients with particular clinical features, treatment responses, and…
Abstract Number: 1343 • 2018 ACR/ARHP Annual Meeting
A Novel Autoantibody Against DNA Damage Binding Protein-1 in Idiopathic Inflammatory Myopathy
Yuji Hosono^1,2, Ran Nakashima¹, Koji Kitagori¹, Kosaku Murakami¹, Hajime Yoshifuji¹, Koichiro Ohmura³ and Tsuneyo Mimori¹, ¹Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ³Department of Rheumatology and Clinical Immunology, Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
Background/Purpose: Many kinds of autoantibodies are detected in idiopathic inflammatory myopathy (IIM) patients. Some of them are useful to diagnose, predict the clinical course, and…
Abstract Number: 1344 • 2018 ACR/ARHP Annual Meeting
Anti-Splicing Factor Proline/Glutamine-Richautoantibodies Rarely Co-Exist with Anti-Melanoma Differentiation-Associated Gene 5 Autoantibodies in a Cohort of Dermatomyositis Patients from the United States
Yuji Hosono¹, Iago Pinal-Fernandez¹, Katherine Pak¹, Jemima Albayda², Eleni Tiniakou³, Julie J. Paik⁴, Christopher A. Mecoli⁵, Sonye K. Danoff⁶, Lisa Christopher-Stine⁶ and Andrew Mammen^1,7, ¹National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Internal Medicine/Rheumatology, Johns Hopkins University, Baltimore, MD, ⁶Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, ⁷Neurology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Anti-melanoma differentiation-associated gene 5 (MDA5) autoantibodies are common among Japanese dermatomyositis (DM) and clinically amyopathic DM (CADM) patients who develop rapidly progressive interstitial lung…
Abstract Number: 1345 • 2018 ACR/ARHP Annual Meeting
Association of HLA-DRB1*0301 with Antisynthetase Syndrome in Spanish Patients
Raquel Lopez-Mejías¹, Sara Remuzgo-Martínez¹, Fernanda Genre¹, Verónica Pulito-Cueto¹, Norberto Ortego Centeno², Eva Perez Pampín³, Antonio Mera³, Julia Martínez-Barrio⁴, Francisco Javier López Longo⁴, Verónica Mijares¹, Leticia Lera-Gomez¹, Sonia Fernández Rozas¹, Victor Mora Cuesta⁵, David Iturbe Fernández¹, Jose Manuel Cifrian Martinez¹, Fredeswinda Romero Bueno⁶, Olga Sanchez-Pernaute⁶, Ricardo Blanco¹, Laura Riesco-Dávila⁷, Laura Nuño⁸, María Gema Bonilla Hernán⁹, Alejandro Balsa⁹, Ernesto Trallero-Araguás¹⁰, Albert Selva O'Callaghan¹⁰, Javier Martin¹¹, Javier Llorca¹², Santos Castañeda¹³, Javier Gonzalo Ocejo⁷, Lorenzo Cavagna¹⁴ and Miguel Angel González-Gay^1,15,16, ¹Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, Santander, Spain, ²Systemic Autoimmune Diseases Unit, Hospital Clínico San Cecilio, Granada, Spain, ³Rheumatology Division. Complejo Hospitalario Universitario de Santiago, Santiago de Compostela, Spain, ⁴Rheumatology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁵Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, Santender, Spain, ⁶Rheumatology Division. Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, ⁷Immunology Division, Hospital Universitario Marqués de Valdecilla, Santander, Spain, Santander, Spain, ⁸Rheumatology, Rheumatology Department, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain, ⁹Rheumatology Department, Hospital Universitario La Paz, IdiPAZ, Madrid, Spain, ¹⁰Rheumatology Department. Hospital Universitario Vall d´Hebron, Barcelona, Spain, ¹¹Instituto de Parasitología y Biomedicina ‘López-Neyra’, CSIC, PTS Granada, Granada, Spain., Granada, Spain, ¹²Division of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, Santander, Spain, Santander, Spain, ¹³Rheumatology, Rheumatology Department, Hospital Universitario de La Princesa, IIS-IP, Madrid, Spain, ¹⁴Division of Rheumatology, University and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, ¹⁵School of Medicine, University of Cantabria, Santander, Spain, ¹⁶Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
Background/Purpose: Antisynthetase syndrome (ASSD) is an inflammatory connective tissue disease characterized by the classic triad: arthritis, myositis, and interstitial lung disease (ILD) [1-3]. Raynaud’s phenomenon,…
Abstract Number: 1346 • 2018 ACR/ARHP Annual Meeting
Anti-NT5c1A Autoantibodies As Biomarkers in Inclusion Body Myositis
Adam Amlani¹, Mark Tarnopolsky², Lauren Brady², Ignacio Garcia de la Torre³, Michael Mahler⁴, May Choi⁵ and Marvin J. Fritzler⁵, ¹Medicine, University of Calgary, Calgary, AB, Canada, ²Department of Pediatrics and Medicine, McMaster University Medical Center, Hamilton, ON, Canada, ³University of Guadalajara, Guadalajara, Mexico, ⁴Research and Development, Inova Diagnostics, San Diego, CA, ⁵Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
Background/Purpose: Sporadic Inclusion Body Myositis (sIBM) is an insidious onset, idiopathic inflammatory myopathy (IIM) with high morbidity. There has not been a reliable biomarker to…
Abstract Number: 1347 • 2018 ACR/ARHP Annual Meeting
A Semi-Quantitative Whole Body Magnetic Resonance Imaging Assessment Tool to Define Musculoskeletal Abnormalities in Patients with Idiopathic Inflammatory Myopathies
Sara Faghihi-Kashani¹, Lisa G. Rider², David Bluemke³, Ashkan Malayeri⁴, Evrim Turkbey⁴, Joseph Shrader⁵, John McGrath⁶, Elizabeth Jones⁷, Jamie Marco⁸, Frederick W. Miller⁹ and Adam Schiffenbauer¹⁰, ¹Environmental Autoimmunity Group, National Institute of Environmental Health, Bethesda, MD, ²Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, ³Department of Radiology, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁴Radiology and Imaging Sciences, National Institutes of Health, Bethesda, MD, ⁵Rehabilitation Medicine, National Institutes of Health, Bethesda, MD, ⁶Social and Scientific Systems, Inc., Durham, NC, ⁷Radiology and Imaging Sciences, National Institutes of Health Clinical Center, Bethesda, MD, ⁸Radiology and Imaging Sciences National Institutes of Health, Bethesda, MD, ⁹Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, ¹⁰NIEHS, NIH, Bethesda, MD
Background/Purpose: There is a lack of standardized methodology for assessing whole body MRI (WBMRI) in idiopathic inflammatory myopathy (IIM) patients. This leads to difficulty in…
Abstract Number: 1348 • 2018 ACR/ARHP Annual Meeting
Quantitative High Throughput Screening of Small Molecules to Inhibit Interferon-Stimulated Major Histocompatibility Complex Class I in Myositis Muscle
Travis Kinder, Patricia Dranchak and James Inglese, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD
Background/Purpose: Common molecular and histological features of idiopathic inflammatory myopathies (myositis) include activation of the type 1 interferon (IFN) response and aberrant expression of major…
Abstract Number: 1349 • 2018 ACR/ARHP Annual Meeting
Rnaseq of Peripheral Blood Mononuclear Cells from Juvenile Dermatomyositis, Necrotizing Myopathy and Controls Are an Aid in Diagnosis
Chiang-Ching Huang¹, Elisha D.O. Roberson², Gabrielle A. Morgan³, Hua Huang⁴, Victoria Hans³ and Lauren M. Pachman^5,6, ¹Zilber School of Public Health, University of Wisconsin at Milwaukee, Milwaukee, WI, ²Depts. of Medicine and Genetics, Division of Rheumatology, Washington University, St. Louis, MO, ³Cure JM Program of Excellence in Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ⁴Zilber School of Public Health, University of Wisconsin, Milwaukee, Milwaukee, WI, ⁵Cure JM Program of Excellence in Juvenile Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, ⁶Pediatric Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose: The HMG-Cr form of Necrotizing Myopathy (NM) is a relatively newly recognized entity within the constellation of pediatric inflammatory myopathies. The purpose of this…
Abstract Number: 1350 • 2018 ACR/ARHP Annual Meeting
Elevated Serum Levels of Soluble CD146 and CD146 Autoantibody in Patients with Polymyositis/Dermatomyositis
Eri Watanabe¹, Takahisa Gono^1,2, Hiroki Yabe¹, Masataka Kuwana², Kazunori Kato³ and Chihiro Terai¹, ¹Department of Rheumatology, Saitama Medical Center, Jichi Medical University, Saitama, Japan, ²Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, ³Department of Biomedical Engineering, Faculty of Science and Engineering, Toyo University, Saitama, Japan
Background/Purpose: CD146 is a transmembrane glycoprotein belong to immunoglobulin superfamily, acts as adhesion molecule for the maintenance of cell monolayer. Human endothelial cells constitutively express…
Abstract Number: 1351 • 2018 ACR/ARHP Annual Meeting
In Situ Dendritic Cell Characterization in Idiopathic Inflammatory Myopathies
Iazsmin Bauer Ventura¹, Daniel Reilly², Peter Pytel³ and Vladimir Liarski², ¹Medicine, Section of Rheumatology, University of Chicago, Chicago, IL, ²Medicine, Section of Rheumatology, University of Chicago, chicago, IL, ³Medicine, Section of Pathology, University of Chicago, chicago, IL
Background/Purpose: The Idiopathic Inflammatory Myopathies (IIM) are the largest number of acquired and potentially treatable muscle disorders. Nevertheless, there are currently no FDA or EMA-approved…
Abstract Number: 1352 • 2018 ACR/ARHP Annual Meeting
Low Density Granulocytes in Idiopathic Inflammatory Myopathy
David Fernandez¹, Linjia Jia², Mikhail Olferiev³, Annel M. Fernandez⁴, JoAnn Vega⁵, Kerri Merritt⁶, Michael Lockshin⁷ and Peggy Crow¹, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ³Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, New York, NY, ⁴Medicine- Rheumatology/ Research, Hospital for Special Surgery, New York, NY, ⁵Medicine - Rheumatology / Research, Hospital for Special Surgery, New York, NY, ⁶Hospital for Special Surgery, New York, NY, ⁷Barbara Volcker Center, Hospital for Special Surgery, New York, NY
Background/Purpose: Idiopathic Inflammatory Myopathy (IIM) is a group of autoimmune diseases characterized by immune-mediated injury to skeletal muscle, including polymyositis (PM) and dermatomyositis (DM). Recent…
Abstract Number: 1353 • 2018 ACR/ARHP Annual Meeting
Autophagy Marker LC3 Accumulates in Immune-Mediated Necrotizing Myopathy Muscle Fibres
Margherita Giannini¹, Francesco Girolamo², Anna Lia², Angela Amati², Luigi Serlenga², Dario D'Abbicco³, Marilina Tampoia⁴, Maria Trojano² and Florenzo Iannone¹, ¹D.E.T.O., Rheumatology Unit - D.E.T.O. - University of Bari (ITALY), Bari, Italy, ²Department of Basic Medical Sciences, Neuroscience and Sense Organs, Unit of Neurophysiopathology, Policlinico Hospital, University of Bari, BARI, Italy, ³Institute of General Surgery ‘G Marinaccio’ (DETO), Policlinico Hospital, University of Bari, BARI, Italy, ⁴Laboratory of Clinical Pathology, University Hospital of Bari, BARI, Italy
Background/Purpose: To investigate the expression of autophagy marker LC3, localization of macrophages and accumulation of misfolded proteins in myofibres of immune-mediated necrotizing myopathy (IMNM) muscle…
Abstract Number: 1354 • 2018 ACR/ARHP Annual Meeting
Correlates of Neuropathic Pain in Knee Osteoarthritis: The Modified Paindetect Questionnaire and the Osteoarthritis Initiative
Joshua Bernick¹, Wilma M. Hopman^2,3, Marc C. Hochberg⁴ and Jacqueline Hochman⁵, ¹Queen's University, Kingston, ON, Canada, ²Research Methodologist, Kingston General Health Research Institute, Queen's University, Kingston, ON, Canada, ³Adjunct Faculty, Department of Public Health Sciences, Faculty of Medicine, Queen's University, Kingston, ON, Canada, ⁴Head, Division of Rheumatology & Clinical Immunology; Vice Chair, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, ⁵Women's College Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: Cumulative evidence suggests central sensitization contributes to a neuropathic-like phenotype in a subset of patients with knee osteoarthritis (OA). Using a variety of validated…
Abstract Number: 1355 • 2018 ACR/ARHP Annual Meeting
Asymptomatic Hyperuricemia Is Associated with Increased Prevalence of Symptomatic Knee Osteoarthritis: Data from Third National Health and Nutrition Examination Survey
Shudan Wang^1,2, Michael Pillinger³, Svetlana Krasnokutsky Samuels⁴ and Kamil E. Barbour⁵, ¹Department of Medicine, Division of Rheumatology, NYU School Medicine, New York City, NY, ²Medicine/Rheumatology, VA Medical Center- Manhattan, New York, NY, ³Medicine/Rheumatology, NYU School of Medicine, New York, NY, ⁴NYU School of Medicine, New York, NY, ⁵Arthritis Program, Centers for Disease Control and Prevention, Atlanta, GA
Background/Purpose: Inflammation plays a pathogenetic role in OA, and catabolic cytokines including IL-1β potentiate joint space narrowing. Elevated serum urate (sUA) levels promote crystal-induced stimulation…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].